Could you clarify a couple of details so I can give you a precise, useful timeline?
- Region(s) of interest (US, EU, other markets)?
- Horizon (next 2–3 years, 5–7 years, longer)?
- Do you want:
- a) ustekinumab/Stelara biosimilar launch timelines (i.e., when competitors might launch biosimilars if patent/IP barriers fall), or
- b) the broader Stelara IP landscape (patent expiry, data exclusivity, litigation) plus competing IL‑12/23/IL‑23 pathway therapies?
What I can provide right now (high level, as of mid-2024):
- Stelara IP status
- Stelara (ustekinumab) is protected by Janssen's patent portfolio and regulatory data protections in major markets. No approved ustekinumab biosimilars in the US or EU as of mid‑2024.
- Exact patent expiry and litigation outcomes vary by jurisdiction and patent family. In many markets, the core IP protections and exclusivities cover products like Stelara for the main indications, and these can extend into the late 2020s in some cases.
- Biologics data exclusivity (e.g., 12 years in the US under BPCIA) provides additional protection even if patents lapse, though the interaction with patent settlements and litigation can alter timelines.
- Biosimilar/competitor landscape (context)
- Direct Stelara biosimilars would compete in the same indications (psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis).
- Other therapies in the same treatment space include approved IL‑23/IL‑12/23 pathway agents (e.g., guselkumab, risankizumab, tildrakizumab) and broader psoriasis biologics (adalimumab, secukinumab, ixekizumab, etc.). These are not Stelara biosimilars, but they affect competitive dynamics and payer/switching behavior.
- Several companies have development programs for ustekinumab biosimilars or follow-on biologics, but as of 2024 none had approved ustekinumab biosimilars in the US/EU. Timelines are highly contingent on patent status, patent litigation outcomes, and regulatory submissions.
If you want, I can assemble:
- A region-specific, 5-year timeline table for potential ustekinumab biosimilar launches, with likely windows (preclinical/phase I–III, submission, approval) and known blockers.
- A slide-ready summary of key IP expiry milestones and how they map to possible biosimilar entry windows.
- A competitor landscape map showing where major IL‑12/23/IL‑23 products stand and how that influences timing and strategy.
Would you like me to pull current, region-specific details and provide a detailed timeline with sources? If so, tell me the region(s) and horizon you care about.